Overview

Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the treatment effect of Panitumumab in combination with chemotherapy versus chemotherapy alone as first line therapy for metastatic and/or recurrent squamous cell carcinoma of the head and neck.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Monoclonal
Cisplatin